Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Isaac S., Bhatia, Shailender, Kaufman, Howard L., Lipson, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865292/
https://www.ncbi.nlm.nih.gov/pubmed/29566749
http://dx.doi.org/10.1186/s40425-018-0335-9
_version_ 1783308653203292160
author Chan, Isaac S.
Bhatia, Shailender
Kaufman, Howard L.
Lipson, Evan J.
author_facet Chan, Isaac S.
Bhatia, Shailender
Kaufman, Howard L.
Lipson, Evan J.
author_sort Chan, Isaac S.
collection PubMed
description Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.
format Online
Article
Text
id pubmed-5865292
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58652922018-03-27 Immunotherapy for Merkel cell carcinoma: a turning point in patient care Chan, Isaac S. Bhatia, Shailender Kaufman, Howard L. Lipson, Evan J. J Immunother Cancer Research Article Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients. BioMed Central 2018-03-23 /pmc/articles/PMC5865292/ /pubmed/29566749 http://dx.doi.org/10.1186/s40425-018-0335-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chan, Isaac S.
Bhatia, Shailender
Kaufman, Howard L.
Lipson, Evan J.
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title_full Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title_fullStr Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title_full_unstemmed Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title_short Immunotherapy for Merkel cell carcinoma: a turning point in patient care
title_sort immunotherapy for merkel cell carcinoma: a turning point in patient care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865292/
https://www.ncbi.nlm.nih.gov/pubmed/29566749
http://dx.doi.org/10.1186/s40425-018-0335-9
work_keys_str_mv AT chanisaacs immunotherapyformerkelcellcarcinomaaturningpointinpatientcare
AT bhatiashailender immunotherapyformerkelcellcarcinomaaturningpointinpatientcare
AT kaufmanhowardl immunotherapyformerkelcellcarcinomaaturningpointinpatientcare
AT lipsonevanj immunotherapyformerkelcellcarcinomaaturningpointinpatientcare

Ejemplares similares